Passage BIO, Inc S-4/A, filed Oct 8, 2026

Passage BIO, Inc. (PASG)

Passage Bio and Remix amended their merger agreement to combine at an assumed exchange ratio of 0.1727, with Passage Bio renamed Remix Therapeutics, Inc. and expected to trade under “RMTX.” A concurrent financing is expected to generate approximately $100.0 million. AI summary